Doravirine/lamivudine/tenofovir, sold under the brand name Delstrigo, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS.[5][6] It contains doravirine, lamivudine, and tenofovir disoproxil.[7][6] It is taken by mouth.[5]
In the United States, it was approved by the Food and Drug Administration (FDA) for the treatment of HIV-1 infection in August 2018.[7][8][9]
External links
References
- PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION: DELSTRIGO Pdf.hres.ca, retrieved 5 June 2022^
- Drug and medical device highlights 2018: Helping you maintain and improve your health Health Canada, 14 October 2020, retrieved 17 April 2024^
- Delstrigo 100 mg /300 mg /245 mg film-coated tablets - Summary of Product Characteristics (SmPC) Medicines.org.uk, 8 July 2020, retrieved 1 October 2020^
- Delstrigo EPAR European Medicines Agency (EMA), 21 September 2018, retrieved 1 October 2020^
- Delstrigo- doravirine, lamivudine, and tenofovir disoproxil fumarate tablet, film coated DailyMed, 10 October 2019, retrieved 31 July 2020^
- Common Drug Review New Combination Product: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination (Delstrigo) CADTH Common Drug Reviews, June 2019^
- FDA Approves Merck's Delstrigo (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and Pifeltro (doravirine), an NNRTI, Both for the Treatment of HIV-1 in Appropriate Patients Merck & Co., 30 August 2018^
- Delstrigo approval letter Food and Drug Administration (FDA), 2018-08-30, retrieved 10 September 2019^
- Drug Approval Package: Pifeltro (doravirine) U.S. Food and Drug Administration (FDA), 9 October 2018, retrieved 22 September 2020^